Epperly Melissa B,'s Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Sep 17, 2026
- Accession no.
- 0001807359-26-000014
- Filed
- Sep 17, 2026, 6:43 PM ET
- Trade date
- Sep 15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $196.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Epperly Melissa B,CIK 0001807359 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Common Shares | SSaleDisposed | −4,338 | $39.65 | −$172,001.7 | 10,500 | Direct | |
| Sep 15, 2026 | Common Shares | SSaleDisposed | −600 | $40.38 | −$24,228 | 9,900 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.